AFREZZA™ is a novel, ultra rapid acting mealtime insulin therapy developed by Mannkind Corporation and marketed by Sanofi. Visit the official site www.afrezza.com for more information. The investor/patient should not rely on this blog as it could be inaccurate & incomplete. The blog was originally written for investors to get a better understanding of the drug while it was in the development stage. As Afrezza is approved, the author does not wish to post anymore.